mProX™ Human PRKCE Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- Kinase Cell Lines
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryBased on this stable cell line, we also provide cell-based in vitro assays to evaluate the effects of your compounds or antibodies.
Product Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
There are currently no Customer reviews or questions for mProX™ Human PRKCE Stable Cell Line (S01YF-1023-PY65). Click the button above to contact us or submit your feedback about this product.
Skyler Davis (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Alex Smith (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Published Data
Fig.1 The MTS assay was conducted in GBC cells, which had been transfected with the PRKCE construct or PRKCE siRNAs.
A decrease in PRKCE expression resulted in a lowered IC50 of gemcitabine and an augmented tumor-killing efficacy in NOZ and GBC-SD cells, while conversely, PRKCE overexpression led to a notable increase in the IC50 of gemcitabine, thereby promoting heightened chemoresistance.
Ref: Wang, Hui, et al. "miR-218-5p restores sensitivity to gemcitabine through PRKCE/MDR1 axis in gallbladder cancer." Cell death & disease 8.5 (2017): e2770-e2770.
Pubmed: 28492560
DOI: 10.1038/cddis.2017.178
Research Highlights
Zafar, Sameen. et al. "Exploring the prognostic significance of PKCε variants in cervical cancer." BMC cancer, 2023.
In this study, pathogenic variations in different domains of Protein Kinase C-epsilon (PKCε) were identified through bioinformatics tools and molecular dynamic simulation. The association of its variants, namely rs1553369874 and rs1345511001, with cervical cancer was determined, along with an assessment of their impact on PKCε's protein-protein interactions. The analysis revealed that these genetic variants were associated with cervical cancer and promoted aberrant interactions with Smad3, potentially activating oncogenic pathways. These findings suggest the prognostic significance of PRKCE gene variants rs1553369874 and rs1345511001. Further validation may enable their use as clinical prognostic markers and therapeutic targets for cervical cancer.
Zafar, Sameen. et al. "Exploring the prognostic significance of PKCε variants in cervical cancer." BMC cancer, 2023.
Pubmed:
37667176
DOI:
10.1186/s12885-023-11236-z
La Cognata, Valentina. et al. "The ε-Isozyme of Protein Kinase C (PKCε) Is Impaired in ALS Motor Cortex and Its Pulse Activation by Bryostatin-1 Produces Long Term Survival in Degenerating SOD1-G93A Motor Neuron-like Cells." International journal of molecular sciences, 2023.
Amyotrophic lateral sclerosis (ALS) is a rapidly advancing, ultimately fatal neurodegenerative ailment. It results from the gradual loss of upper and lower motor neurons in the brain and spinal cord. Irregularities in multiple PKC-mediated signal transduction pathways in ALS have been identified, involving impaired expression or altered activity of PKC isozymes (α, β, ζ, and δ). This rewriting explores the distribution and cellular localization of the protein kinase C ε-isozyme (PKCε) in human postmortem motor cortex specimens and highlights a substantial decline in both PKCε mRNA (PRKCE) and protein immunoreactivity in some sporadic ALS patients. Additionally, it investigates steady-state levels of pan and phosphorylated PKCε in doxycycline-activated NSC-34 cell lines carrying human wild-type (WT) or mutant G93A SOD1, as well as the prolonged effect of transient Bryostatin-1-induced PKCε activation. Notably, G93A-SOD1 cells exhibited a marked reduction in the phosphoPKCε/panPKCε ratio compared to the WT. Moreover, brief Bryostatin-1-induced PKCε activation conferred long-term survival to degenerating G93A-SOD1 cells under two distinct cell death conditions (serum starvation and chemokine-induced toxicity). Collectively, these findings underscore PKCε's involvement in ALS pathophysiology and propose its pharmacological modulation as a potential neuroprotective strategy, particularly for certain sporadic ALS patients.
La Cognata, Valentina. et al. "The ε-Isozyme of Protein Kinase C (PKCε) Is Impaired in ALS Motor Cortex and Its Pulse Activation by Bryostatin-1 Produces Long Term Survival in Degenerating SOD1-G93A Motor Neuron-like Cells." International journal of molecular sciences, 2023.
Pubmed:
37629005
DOI:
10.3390/ijms241612825